...
机译:对Adam17的单克隆抗体通过抑制EGFR和非EGFR介导的途径来抑制肿瘤生长
MedImmune LLC Oncol Res Gaithersburg MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
Champ Oncol Inc Baltimore MD USA;
Champ Oncol Inc Baltimore MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
MedImmune LLC Oncol Res Gaithersburg MD USA;
机译:对Adam17的单克隆抗体通过抑制EGFR和非EGFR介导的途径来抑制肿瘤生长
机译:表皮生长因子受体(EGFR EGFR)抑制性单克隆抗体和EGFR EGFR酪氨酸激酶抑制剂对角蛋白酶细胞先天免疫应答具有明显的影响
机译:通过将EGFR障碍和免疫激活与直接肿瘤细胞杀死组合,肿瘤靶向抗EGFR X抗PD1抗PD1抗PD1抗PD1抗PD1双特异性抗体抑制EGFR过表达肿瘤生长
机译:纳米共轭物与不同单克隆抗体的抑制肿瘤血管生成重要分子靶标的发展。
机译:抑制致瘤蛋白酶的高选择性单克隆抗体的产生
机译:通过将EGFR障碍和免疫激活与直接肿瘤细胞杀死组合肿瘤靶向抗EGFR X抗PD1抗PD1抗PD1抗PD1抗PD1双特异性抗体抑制EGFR过表达肿瘤生长
机译:单独使用抗表皮生长因子受体单克隆抗体ICR62的人结直肠肿瘤细胞对抗表皮生长因子受体单克隆抗体的反应。与EGFR酪氨酸激酶抑制剂吉非替尼结合
机译:抑制肿瘤血管生成的受体单克隆抗体